Bull World Health Organ 2015;93:457–467 | doi: http://dx.doi.org/10.2471/BLT.14.147215
Joint Action for Results
UNAIDS Outcome Framework: Business Case 2009–2011
Participant Manual
February 2011
Edition 3.0
Technical Brief
Damon Barrett, Gonçalo Figueiredo Augusto, Martiani Oktavia, Jeanette Olsson, Mira Schneiders and Kate Welch provided background papers and literature reviews which informed this technical series.
Downloaded from https://aidsinfo.nih.gov/guidelines on 11/27/2019
Visit the AIDSinfo website to access the most up-to-date guideline.
Register for e-mail notification of guideline updates at https://aidsinfo.nih.gov/e-news.
.This assessment was conducted using focus group discussion(FGD)with peopleliving with disabilities who were members of the Ethiopian National Association of the Deaf(Person with hearing impairment), Ethiopian National Association of the Deaf -Blind ( Person with hearing and visual impairment), Ethi...opian National Association of the Blind (Person with visual impairment), Ethiopian National Association of the Physically Handicapped (Person with physical impairment), Ethiopian National Association of Intellectual Disability (Person with intellectual disability). In total 152 people living with disabilities participated in the discussion groups.Results from the assessment were analysed based on themes and are presented by each group in the following report.
more
HIV & AIDS Treatment in Practice No.199
Severe bacterial infections are a leading cause of morbidity and mortality among people with advanced HIV disease, after tuberculosis and cryptococcal disease. For countries to reach the end-AIDS targets for 2030, there is a need to establish a roadmap for managing severe bacterial infections and re...duce mortality. The purpose of the meeting was to
Review the current research and implementation data on the use of prophylactic antibiotics (specifically azithromycin/macrolides) as part of the AHD package of care; To review options for preventing SBIs that are in line with goals of reducing AMR; Present the current evidence on diagnostics for SBI; Discuss research gaps and implementation challenges.
more
World Health Organization Department of Reproductive Health and Research
Brocher Foundation, Hermance, Geneva, Switzerland, 27–29 April 2016
Research Article
PLOS ONE | DOI:10.1371/journal.pone.0169530 February 16, 2017
PLOS ONE | https://doi.org/10.1371/journal.pone.0210937
February 5, 2019
Epidemiology
Chagas disease (American trypanosomiasis) is caused by the protozoan parasite Trypanosoma cruzi, and transmitted to humans by infected triatomine bugs, and less commonly by transfusion, organ transplant, from mother to infant, and in rare instances, by ingestion of contaminated food or... drink.1-4 The hematophagous triatomine vectors defecate during or immediately after feeding on a person. The parasite is present in large numbers in the feces of infected bugs, and enters the human body through the bite wound, or through the intact conjunctiva or other mucous membrane.
Vector-borne transmission occurs only in the Americas, where an estimated 8 to 10 million people have Chagas disease.5 Historically, transmission occurred largely in rural areas in Latin America, where houses built of mud brick are vulnerable to colonization by the triatomine vectors.4 In such areas, Chagas disease usually is acquired in childhood. In the last several decades, successful vector control programs have substantially decreased transmission rates in much of Latin America, and large-scale migration has brought infected individuals to cities both within and outside of Latin America.
more
PQDx 0181-031-00
WHO PQ Public Report
March/2017, version 3.0
In 2014, the World Heart Federation (WHF) launched
an initiative to develop a series of Roadmaps [1e6]. Their
aim is to identify potential roadblocks on the pathway to
effective prevention, detection, and management of cardiovascular disease (CVD), along with evidence-based
solutions to overcome... them. The resulting documents
provide a framework to translate strategic intent into action
on integrating epidemiology, population, and cardiovascular outcome trial data into national plans for optimal
CVD management.
more